Chronic insomnia

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Purpose of Review: This article provides an overview of current strategies for evaluating and treating patients who experience chronic insomnia.Recent Findings: The US Food and Drug Administration (FDA) has approved several medications for the treatment of insomnia that incorporate a variety of pharmacodynamic and pharmacokinetic properties, thus allowing the development of a customized therapeutic approach. FDA-approved medications include γ-aminobutyric acid-modulating benzodiazepine receptor agonists, a melatonin receptor agonist, and a histamine receptor agonist. Psychological and behavioral techniques combined as cognitive-behavioral therapy also have been shown to be effective in the treatment of chronic insomnia.Summary: Insomnia is the most common sleep disturbance and represents a chronic condition for many people. Difficulty falling asleep and maintaining sleep are highly prevalent problems in patients with neurologic disorders. Multiple factors typically contribute to insomnia. Accordingly, a rather broad approach to evaluating patients is warranted. Evidence-based guidelines support the use of cognitive and behavioral strategies and selected medications in the treatment of patients with chronic insomnia.

Original languageEnglish (US)
Pages (from-to)50-66
Number of pages17
JournalCONTINUUM Lifelong Learning in Neurology
Issue number1
StatePublished - Feb 2013

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)


Dive into the research topics of 'Chronic insomnia'. Together they form a unique fingerprint.

Cite this